Mallinckrodt Plc (MNK)

7.24
0.32 4.30
NYSE : Health Technology
Prev Close 7.56
Open 7.57
Day Low/High 7.02 / 7.61
52 Wk Low/High 7.20 / 36.65
Volume 2.50M
Avg Volume 3.08M
Exchange NYSE
Shares Outstanding 83.81M
Market Cap 687.27M
EPS -42.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CSX Heading Down? I'll Let This Train Pass Me by

CSX Heading Down? I'll Let This Train Pass Me by

With earnings that lack much optimism, CSX not a good bet for buying on weakness now.

Mallinckrodt Halts Phase 2B Trial Investigating The Use Of Acthar® Gel (Repository Corticotropin Injection) In Amyotrophic Lateral Sclerosis (ALS)

Mallinckrodt Halts Phase 2B Trial Investigating The Use Of Acthar® Gel (Repository Corticotropin Injection) In Amyotrophic Lateral Sclerosis (ALS)

STAINES-UPON-THAMES, United Kingdom, July 16, 2019 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today announced that it is permanently discontinuing its Phase 2B study designed to assess the efficacy...

Interesting MNK Put And Call Options For August 30th

Interesting MNK Put And Call Options For August 30th

Investors in Mallinckrodt plc saw new options become available today, for the August 30th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new August 30th contracts and identified one put and one call contract of particular interest.

August 23rd Options Now Available For Mallinckrodt (MNK)

August 23rd Options Now Available For Mallinckrodt (MNK)

Investors in Mallinckrodt plc saw new options begin trading today, for the August 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new August 23rd contracts and identified one put and one call contract of particular interest.

Mallinckrodt To Report Earnings Results For Second Quarter 2019

Mallinckrodt To Report Earnings Results For Second Quarter 2019

STAINES-UPON-THAMES, United Kingdom, July 1, 2019 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, announced today that it will report second quarter 2019 earnings results for the period ending June 28, 2019 on Tuesday,...

August 9th Options Now Available For Mallinckrodt (MNK)

August 9th Options Now Available For Mallinckrodt (MNK)

Investors in Mallinckrodt plc saw new options begin trading today, for the August 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new August 9th contracts and identified one put and one call contract of particular interest.

Notable Monday Option Activity: MNK, LAUR, SBH

Notable Monday Option Activity: MNK, LAUR, SBH

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mallinckrodt plc , where a total of 31,707 contracts have traded so far, representing approximately 3.2 million underlying shares. That amounts to about 99.6% of MNK's average daily trading volume over the past month of 3.2 million shares.

Mallinckrodt Achieves 50 Percent Enrollment For Phase 2B Trial Investigating The Use Of Acthar® Gel (Repository Corticotropin Injection) In Amyotrophic Lateral Sclerosis (ALS)

Mallinckrodt Achieves 50 Percent Enrollment For Phase 2B Trial Investigating The Use Of Acthar® Gel (Repository Corticotropin Injection) In Amyotrophic Lateral Sclerosis (ALS)

STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ --  Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed...

MNK August 2nd Options Begin Trading

MNK August 2nd Options Begin Trading

Investors in Mallinckrodt plc saw new options become available today, for the August 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new August 2nd contracts and identified one put and one call contract of particular interest.

All Primary And Secondary Outcome Targets Met In Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) With Data Presented At The European Congress Of Rheumatology 2019 (EULAR)

All Primary And Secondary Outcome Targets Met In Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) With Data Presented At The European Congress Of Rheumatology 2019 (EULAR)

-- Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR¹ at Week 12 --

Mallinckrodt Becomes Oversold (MNK)

Mallinckrodt Becomes Oversold (MNK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Mallinckrodt To Present At BMO Capital Markets 2019 Prescriptions For Success Healthcare Conference

Mallinckrodt To Present At BMO Capital Markets 2019 Prescriptions For Success Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, June 11, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019, at the BMO Capital Markets 2019 Prescriptions for Success Healthcare...

MNK July 26th Options Begin Trading

MNK July 26th Options Begin Trading

Investors in Mallinckrodt plc saw new options begin trading today, for the July 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new July 26th contracts and identified one put and one call contract of particular interest.

RM LAW Announces Investigation Of Mallinckrodt Plc

RM LAW Announces Investigation Of Mallinckrodt Plc

BERWYN, Pa., May 31, 2019 /PRNewswire/ --  RM LAW, P.

Mallinckrodt To Present At Raymond James Life Sciences And Medtech Conference

Mallinckrodt To Present At Raymond James Life Sciences And Medtech Conference

STAINES-UPON-THAMES, United Kingdom, May 31, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Wednesday, June 19, 2019, at the Raymond James Life Sciences and MedTech Conference at the...

Interesting MNK Put And Call Options For July 12th

Interesting MNK Put And Call Options For July 12th

Investors in Mallinckrodt plc saw new options become available today, for the July 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new July 12th contracts and identified one put and one call contract of particular interest.

Mallinckrodt Announces Positive Open-Label Results From Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial In Rheumatoid Arthritis (RA) To Be Presented At The European Congress Of Rheumatology 2019 (EULAR)

Mallinckrodt Announces Positive Open-Label Results From Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial In Rheumatoid Arthritis (RA) To Be Presented At The European Congress Of Rheumatology 2019 (EULAR)

-- Data from a sizable (n=259) open-label part of the Phase 4 study showed 62.5 percent of patients with persistently active RA achieved low disease activity at Week 12, a robust response percentage in this more refractory patient population, and the study's primary outcome measure --

Mallinckrodt Rises After Announcing Plans to Spin Off Specialty Generics Unit

Mallinckrodt Rises After Announcing Plans to Spin Off Specialty Generics Unit

Mallinckrodt plans to spin off its specialty generics business. It will be renamed Sonorant Therapeutics.

Mallinckrodt Updates Plans For Company Separation And Spin-Off Of Specialty Generics Business To Shareholders

Mallinckrodt Updates Plans For Company Separation And Spin-Off Of Specialty Generics Business To Shareholders

-- Announces James Sulat as chairman of the board of directors and Michael Atieh as audit committee chair nominees for new Specialty Generics company -

Baking It In: Cramer's 'Mad Money' Recap (Thursday 5/23/19)

Baking It In: Cramer's 'Mad Money' Recap (Thursday 5/23/19)

Jim Cramer says we need to bake in as much bad news as possible before the market really finds a bottom. There will be more declines ahead.

July 5th Options Now Available For Mallinckrodt (MNK)

July 5th Options Now Available For Mallinckrodt (MNK)

Investors in Mallinckrodt plc saw new options begin trading today, for the July 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new July 5th contracts and identified one put and one call contract of particular interest.

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Mallinckrodt Plc

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Mallinckrodt Plc

NEW YORK, May 22, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Mallinckrodt plc (NYSE: MNK) common stock from April 13, 2016 through May 21, 2019.

LOST MONEY IN MALLINCKRODT? Gibbs Law Group Investigates Potential Securities Claims On Behalf Of Investors

LOST MONEY IN MALLINCKRODT? Gibbs Law Group Investigates Potential Securities Claims On Behalf Of Investors

Mallinckrodt plc shares have declined by nearly 38% in 2019 due to issues with health regulators and accusations of kickbacks.

Mallinckrodt Announces Election Of Carlos V. Paya, M.D., Ph.D. To Its Board Of Directors

Mallinckrodt Announces Election Of Carlos V. Paya, M.D., Ph.D. To Its Board Of Directors

-- New member brings unique blend of industry expertise and clinical experience --

Mallinckrodt Is Circling the Drain - Do Not Go Down With It

Mallinckrodt Is Circling the Drain - Do Not Go Down With It

Let's examine a couple of charts.

Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel

The drugmaker files suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services in order to protect Medicaid patient access to its Acthar gel.

Mallinckrodt Files Suit Against U.S. Department Of Health And Human Services (HHS) And Centers For Medicare And Medicaid Services (CMS) To Protect Medicaid Patient Access To Acthar® Gel

Mallinckrodt Files Suit Against U.S. Department Of Health And Human Services (HHS) And Centers For Medicare And Medicaid Services (CMS) To Protect Medicaid Patient Access To Acthar® Gel

-- Company challenges CMS' unexplained and unlawful reversal of its repeated 2012 written authorizations on calculation of Medicaid Rebates for Acthar Gel --

TheStreet Quant Rating: D (Sell)